Aimovig: New migraine prevention drug approved by FDA

May 21, 2018
  • By Michelle Ewing, Cox Media Group National Content Desk

If you suffer from chronic migraines, relief is here.

According to The Associated Press, the Food and Drug Administration last week approved Aimovig, a monthly shot that aims to reduce migraines. The drug, developed by Amgen Inc. and Novartis AG, is "injected monthly just under the skin using a pen-like device," the AP reported. Its price tag: $6,900 annually before insurance.

>> On ActionNewsJax.com: New drug could reduce migraines

But how does Aimovig work? The FDA said it blocks "the activity of calcitonin gene-related peptide, a molecule that is involved in migraine attacks." Amgen researchers said participants in one study saw their migraines reduced by half and experienced "minor side effects" like colds, the AP reported.

>> Read more trending news 

If Aimovig doesn't sound right for you, you're still in luck: Three similar shots and various pills to combat migraines are in the works.

Read more here.

– The Associated Press contributed to this report.